Furthermore, an ATP-site kinase inhibitor with activity against Hck known as A-419259 (Wilson et al., 2002) suppressed the growth of patient AML cells in engrafted immunocompromised mice (Saito et al., 2013), although subsequent studies have shown that this compound is also active against Fgr and Lyn as well as Flt3. Here, HCK is linked to acute myeloid leukemia.